# Pharmacokinetics, Acceptability and Safety of Famciclovir in Infants (1 Month to Less Than 12 Months) With Herpes Simplex Infection

> **NCT00448227** · PHASE2 · COMPLETED · sponsor: **Novartis** · enrollment: 18 (actual)

## Conditions studied

- Herpes Simplex

## Interventions

- **DRUG:** famciclovir

## Key facts

- **NCT ID:** NCT00448227
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-10
- **Primary completion:** 2008-11
- **Final completion:** —
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2011-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00448227

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00448227, "Pharmacokinetics, Acceptability and Safety of Famciclovir in Infants (1 Month to Less Than 12 Months) With Herpes Simplex Infection". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT00448227. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*